[go: up one dir, main page]

MA51673B1 - Composés pour le traitement des troubles dépendants de kinases - Google Patents

Composés pour le traitement des troubles dépendants de kinases

Info

Publication number
MA51673B1
MA51673B1 MA51673A MA51673A MA51673B1 MA 51673 B1 MA51673 B1 MA 51673B1 MA 51673 A MA51673 A MA 51673A MA 51673 A MA51673 A MA 51673A MA 51673 B1 MA51673 B1 MA 51673B1
Authority
MA
Morocco
Prior art keywords
compounds
kinases
treatment
relates
dependent disorders
Prior art date
Application number
MA51673A
Other languages
English (en)
Other versions
MA51673A (fr
Inventor
Wei Xu
Minna Bui
Faming Jiang
Yong Wang
Lynne Canne Bannen
Kin Tso
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of MA51673A publication Critical patent/MA51673A/fr
Publication of MA51673B1 publication Critical patent/MA51673B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/60—Quinoline or hydrogenated quinoline ring systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne des composés de formule (I). Les composés de formule (I) inhibent, régulent et/ou modulent le récepteur de la kinase, en particulier les voies de transduction de signal Axl et Mer associées aux changements des activités cellulaires telles que mentionnées ci-dessus, des compositions qui contiennent ces composés, et des méthodes d'utilisation de ceux-ci pour traiter des maladies et des états dépendant de la kinase. La présente invention concerne également des procédés de fabrication des composés tels que mentionnés ci-dessus, et des compositions qui contiennent ces composés.
MA51673A 2018-01-26 2019-01-25 Composés pour le traitement des troubles dépendants de kinases MA51673B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862622702P 2018-01-26 2018-01-26
US201862758321P 2018-11-09 2018-11-09
EP19704970.3A EP3743070B1 (fr) 2018-01-26 2019-01-25 Composés pour le traitement des troubles dépendants de kinases
PCT/US2019/015297 WO2019148044A1 (fr) 2018-01-26 2019-01-25 Composés destinés au traitement de troubles dépendant de la kinase

Publications (2)

Publication Number Publication Date
MA51673A MA51673A (fr) 2020-12-02
MA51673B1 true MA51673B1 (fr) 2025-10-31

Family

ID=65409544

Family Applications (1)

Application Number Title Priority Date Filing Date
MA51673A MA51673B1 (fr) 2018-01-26 2019-01-25 Composés pour le traitement des troubles dépendants de kinases

Country Status (33)

Country Link
US (2) US11542259B2 (fr)
EP (2) EP4647127A3 (fr)
JP (3) JP7321165B2 (fr)
KR (2) KR20240155380A (fr)
CN (5) CN117820226A (fr)
AU (2) AU2019212801B2 (fr)
BR (1) BR112020015201A2 (fr)
CA (1) CA3088200A1 (fr)
CL (2) CL2020001931A1 (fr)
CO (1) CO2020010465A2 (fr)
CR (2) CR20230287A (fr)
DK (1) DK3743070T3 (fr)
ES (1) ES3048989T3 (fr)
FI (1) FI3743070T3 (fr)
GE (2) GEP20257770B (fr)
HR (1) HRP20251184T1 (fr)
HU (1) HUE073371T2 (fr)
IL (3) IL300824A (fr)
LT (1) LT3743070T (fr)
MA (1) MA51673B1 (fr)
MX (2) MX2020007765A (fr)
MY (1) MY210421A (fr)
PE (2) PE20242219A1 (fr)
PH (1) PH12020551208A1 (fr)
PL (1) PL3743070T3 (fr)
PT (1) PT3743070T (fr)
RS (1) RS67317B1 (fr)
SA (1) SA520412500B1 (fr)
SG (1) SG11202006921PA (fr)
SI (1) SI3743070T1 (fr)
SM (1) SMT202500395T1 (fr)
UA (1) UA128476C2 (fr)
WO (1) WO2019148044A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4647127A3 (fr) * 2018-01-26 2025-12-17 Exelixis, Inc. Composés pour le traitement de troubles dépendant de la kinase
WO2019148043A1 (fr) 2018-01-26 2019-08-01 Exelixis, Inc. Composés destinés au traitement de troubles dépendant de la kinase
WO2020097389A1 (fr) 2018-11-09 2020-05-14 Vivace Therapeutics, Inc. Composés bicycliques
WO2020123800A1 (fr) * 2018-12-13 2020-06-18 Exelixis, Inc. Formes cristallines et formes salines d'un inhibiteur de kinase
EP3914356A1 (fr) * 2019-01-25 2021-12-01 Exelixis, Inc. Composés pour le traitement de troubles dépendant de la kinase
CN109761899B (zh) * 2019-02-14 2022-11-15 广州六顺生物科技股份有限公司 喹啉衍生物、其药学上可接受的盐或其溶剂合物、其应用、药物及药物组合物
KR102909464B1 (ko) * 2019-04-16 2026-01-09 비바체 테라퓨틱스, 인크. 바이사이클릭 화합물
BR112021024300A2 (pt) * 2019-06-03 2022-01-11 Exelixis Inc Formas de sais cristalinas de um inibidor de quinase
AR119069A1 (es) 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
CN110845406B (zh) * 2019-12-04 2021-07-20 广州安岩仁医药科技有限公司 喹啉类化合物的制备方法
EP4103188A4 (fr) * 2020-02-10 2024-04-10 StemSynergy Therapeutics, Inc. Inhibiteurs de myc et leurs utilisations
BR112022021712A2 (pt) * 2020-04-30 2022-12-06 Exelixis Inc Processos para a preparação de um inibidor de quinase
BR112023001792A2 (pt) * 2020-07-31 2023-04-11 Exelixis Inc Combinações para o tratamento de câncer
KR20230104186A (ko) 2020-11-05 2023-07-07 엑셀리시스, 인코포레이티드 키나제 억제제의 약제학적 조성물
TW202241862A (zh) * 2021-02-01 2022-11-01 大陸商江蘇恆瑞醫藥股份有限公司 二甲醯胺類化合物、其製備方法及其在醫藥上的應用
WO2022177557A1 (fr) * 2021-02-17 2022-08-25 Springworks Therapeutics, Inc. Solides cristallins d'inhibiteur de mek n-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodophénylamino)-benzamide et utilisations associées
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
CA3240202A1 (fr) 2021-12-22 2023-06-29 Kirsten Phizackerley Formes cristallines et formes salines d'un inhibiteur de kinase
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN116655626B (zh) * 2023-05-24 2025-03-11 遵义医科大学 一种含咪唑并[l，2-a]吡啶骨架的环丙二酰胺化合物及其制备方法和用途
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途
WO2025253311A1 (fr) 2024-06-04 2025-12-11 Hetero Labs Limited Composés 1,2-dicarboxamide utilisés en tant qu'inhibiteurs de kinase

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804396A (en) 1994-10-12 1998-09-08 Sugen, Inc. Assay for agents active in proliferative disorders
EP2163546B1 (fr) 1995-03-30 2016-06-01 Pfizer Products Inc. Derives de quinazoline
GB9508565D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE69710712T3 (de) 1996-04-12 2010-12-23 Warner-Lambert Co. Llc Umkehrbare inhibitoren von tyrosin kinasen
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
ZA986729B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
ES2925655T3 (es) * 2003-09-26 2022-10-19 Exelixis Inc Moduladores c-Met y métodos de uso
CA2604238C (fr) 2005-04-15 2015-07-07 Neogenix Oncology, Inc. Anticorps monoclonaux recombines et antigenes correspondants contre les cancers du colon et du pancreas
PL2161336T5 (pl) 2005-05-09 2017-10-31 Ono Pharmaceutical Co Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
BRPI0920261A8 (pt) * 2008-10-14 2016-01-19 Xi Ning Composto, composição farmacêutica, uso do composto, e, método para inibir ou modular atividade de proteína quinase em uma amostra biológica
KR20250123237A (ko) 2009-01-16 2025-08-14 엑셀리시스, 인코포레이티드 암의 치료를 위한 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형
EP2213686A1 (fr) 2009-01-28 2010-08-04 Externautics S.p.A. Marqueurs de tumeur et procédés d'utilisation correspondants
EP2214019A1 (fr) 2009-01-28 2010-08-04 Externautics S.p.A. Marqueurs de tumeurs et leurs utilisations
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
EP2494351B1 (fr) 2009-10-26 2016-06-08 Externautics S.p.A. Marqueurs de tumeurs du rectum et du côlon, et leurs méthodes d'utilisation
WO2011051277A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs du sein et leurs méthodes d'utilisation
WO2011051278A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs du poumon et leurs méthodes d'utilisation
WO2011051280A1 (fr) 2009-10-26 2011-05-05 Externautics S.P.A. Marqueurs de tumeurs des ovaires et leurs méthodes d'utilisation
EP2494362B1 (fr) 2009-10-26 2016-06-08 Externautics S.p.A. Marqueurs de tumeur de la prostate et méthodes d'utilisation
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
EP2383578A1 (fr) 2010-04-30 2011-11-02 Externautics S.p.A. Marqueur de tumeur et procédés d'utilisation correspondants
JP5770281B2 (ja) * 2010-07-14 2015-08-26 ベータ ファーマシューティカルズ カンパニー リミテッド ｃ−ＭＥＴチロシンキナーゼ阻害薬として有用な新規な縮合複素環式誘導体
AU2011278950C1 (en) 2010-07-16 2018-11-22 Exelixis, Inc. c-Met modulator pharmaceutical compositions
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
SI2621481T2 (sl) 2010-09-27 2023-02-28 Exelixis, Inc., Dvojni inhibitorji MET in VEGF za zdravljenje proti kastraciji odpornega raka prostate in osteoblastnih kostnih metastaz
CN102093421B (zh) * 2011-01-28 2014-07-02 北京康辰药业有限公司 一种含磷取代基的喹啉类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
AU2012214322B2 (en) 2011-02-10 2017-04-27 Exelixis, Inc. Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
JP2014513129A (ja) 2011-05-02 2014-05-29 エクセリクシス， インク． 癌および骨癌疼痛の治療方法
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
US10166225B2 (en) 2011-09-22 2019-01-01 Exelixis, Inc. Method for treating osteoporosis
US9365516B2 (en) 2011-10-20 2016-06-14 Exelixis, Inc. Process for preparing quinoline derivatives
TW201323864A (zh) 2011-11-08 2013-06-16 Exelixis Inc 定量癌症治療之方法
WO2013070890A1 (fr) 2011-11-08 2013-05-16 Exelixis, Inc. Double inhibiteur de met et vegf pour le traitement du cancer
HK1207587A1 (en) 2012-05-02 2016-02-05 Exelixis, Inc. A dual met - vegf modulator for treating osteolytic bone metastases
CN114129566A (zh) 2012-09-07 2022-03-04 埃克塞里艾克西斯公司 用于治疗肺腺癌的met、vegfr和ret的抑制剂
CN114507282B (zh) 2012-10-04 2025-05-16 达纳－法伯癌症研究所公司 人单克隆抗-pd-l1抗体和使用方法
AU2014232714B2 (en) 2013-03-15 2018-07-19 Exelixis, Inc. Metabolites of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
AU2014248001A1 (en) 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
ES2927651T3 (es) 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
HUE053069T2 (hu) 2013-05-02 2021-06-28 Anaptysbio Inc Programozott halál-1 (PD-1) ellen irányuló ellenanyagok
US10359428B2 (en) 2013-06-14 2019-07-23 Externautics S.P.A. Tumor marker, monoclonal antibodies and methods of use thereof
JP2016540042A (ja) 2013-11-05 2016-12-22 コグネート バイオサービシズ， インコーポレイテッド がんを処置するためのチェックポイント阻害剤および治療薬の組合せ
US10501418B2 (en) 2014-02-14 2019-12-10 Exelixis, Inc. Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N′-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
MA39735A (fr) 2014-03-17 2017-01-25 Exelixis Inc Dosage de préparations de cabozantinib
AR100191A1 (es) 2014-04-25 2016-09-14 Exelixis Inc Método para tratar adenocarcinoma de pulmón
EP3174854B1 (fr) 2014-07-31 2022-08-24 Exelixis, Inc. Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
AU2015301097B2 (en) 2014-08-05 2021-03-04 Exelixis, Inc. Drug combinations to treat multiple myeloma
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
US20180009758A1 (en) * 2015-06-29 2018-01-11 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
US20170342033A1 (en) * 2015-06-29 2017-11-30 Ontogenesis, Llc Multi-Tyrosine Kinase Inhibitors Derivatives and Methods of Use
WO2017004005A1 (fr) * 2015-06-29 2017-01-05 Ontogenesis, Llc Promédicaments n-acylalkyle de pluri-inhibiteurs de la tyrosine kinase et procédés d'utilisation
CA3020749A1 (fr) 2016-04-15 2017-10-19 Exelixis, Inc. Procede de traitement du cancer a cellules renales a l'aide de n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
WO2017184597A1 (fr) 2016-04-19 2017-10-26 Exelixis, Inc. Procédé de traitement du cancer du sein négatif triple
CN105797123A (zh) * 2016-05-18 2016-07-27 王超 一种治疗不孕不育的中药组合物
CN106400155A (zh) * 2016-08-31 2017-02-15 飞佛特种纺织品（宁波）有限公司 一种防老化阳光面料
CN107235896B (zh) * 2016-09-13 2019-11-05 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
JP2019529476A (ja) 2016-09-27 2019-10-17 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｎ−（４−（６，７−ジメトキシキノリン−４−イルオキシ）フェニル）−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボキサミドを用いた尿路上皮癌及び他の尿生殖器悪性腫瘍の治療方法
AU2018210397B2 (en) 2017-01-20 2024-02-29 Exelixis, Inc. Combinations of cabozantinib and atezolizumab to treat cancer
WO2018145621A1 (fr) * 2017-02-07 2018-08-16 恩瑞生物医药科技（上海）有限公司 Composé de quinoléine, procédé de préparation et utilisation médicale associés
JP7166292B2 (ja) 2017-05-26 2022-11-07 エグゼリクシス， インコーポレイテッド Ｎ－｛４－［（６，７－ジメトキシキノリン－４－イル）オキシ］フェニル｝－ｎ’－（４－フルオロフェニル）シクロプロパン－１，１－ジカルボキサミドの塩の結晶性固体形態、製造プロセス、及び使用方法
CN110678180A (zh) 2017-06-09 2020-01-10 埃克塞里艾克西斯公司 治疗癌症的液体剂型
WO2019125798A1 (fr) 2017-12-20 2019-06-27 Angex Pharmaceutical, Inc. Composés de carbamate et d'urée utilisés comme inhibiteurs de multikinases
US20190262330A1 (en) 2017-12-21 2019-08-29 Exelixis, Inc. Method of Treating Hepatocellular Carcinoma Using N-(4-(6,7-dimethoxyquinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (2S)-hydroxybutanedioate
WO2019148043A1 (fr) * 2018-01-26 2019-08-01 Exelixis, Inc. Composés destinés au traitement de troubles dépendant de la kinase
IL302626B2 (en) * 2018-01-26 2025-12-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
EP4647127A3 (fr) * 2018-01-26 2025-12-17 Exelixis, Inc. Composés pour le traitement de troubles dépendant de la kinase
WO2020123800A1 (fr) * 2018-12-13 2020-06-18 Exelixis, Inc. Formes cristallines et formes salines d'un inhibiteur de kinase
EP3914356A1 (fr) * 2019-01-25 2021-12-01 Exelixis, Inc. Composés pour le traitement de troubles dépendant de la kinase
BR112021024300A2 (pt) * 2019-06-03 2022-01-11 Exelixis Inc Formas de sais cristalinas de um inibidor de quinase
AR119069A1 (es) * 2019-06-04 2021-11-24 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de quinasas
BR112022021712A2 (pt) * 2020-04-30 2022-12-06 Exelixis Inc Processos para a preparação de um inibidor de quinase
BR112023001792A2 (pt) * 2020-07-31 2023-04-11 Exelixis Inc Combinações para o tratamento de câncer
KR20230104186A (ko) * 2020-11-05 2023-07-07 엑셀리시스, 인코포레이티드 키나제 억제제의 약제학적 조성물
TW202334090A (zh) * 2021-11-03 2023-09-01 美商艾克塞里克斯公司 用於治療激酶依賴性病症之化合物
CA3240202A1 (fr) * 2021-12-22 2023-06-29 Kirsten Phizackerley Formes cristallines et formes salines d'un inhibiteur de kinase

Also Published As

Publication number Publication date
MX2020007765A (es) 2020-09-25
AU2019212801A1 (en) 2020-08-20
HRP20251184T1 (hr) 2025-12-05
CN117603138A (zh) 2024-02-27
CN117402114A (zh) 2024-01-16
UA128476C2 (uk) 2024-07-24
CN117820226A (zh) 2024-04-05
CR20230287A (es) 2023-07-26
GEAP202415420A (en) 2024-12-25
US20210040076A1 (en) 2021-02-11
FI3743070T3 (fi) 2025-10-16
HUE073371T2 (hu) 2026-01-28
CN111757735A (zh) 2020-10-09
MY210421A (en) 2025-09-22
PE20211203A1 (es) 2021-07-05
WO2019148044A1 (fr) 2019-08-01
SI3743070T1 (sl) 2025-11-28
PT3743070T (pt) 2025-10-27
EP4647127A3 (fr) 2025-12-17
IL321138A (en) 2025-07-01
CL2020001931A1 (es) 2020-12-11
ES3048989T3 (en) 2025-12-12
EP3743070B1 (fr) 2025-07-23
LT3743070T (lt) 2025-11-10
PE20242219A1 (es) 2024-11-19
SMT202500395T1 (it) 2025-11-10
SG11202006921PA (en) 2020-08-28
CN111757735B (zh) 2023-09-22
US20240043414A1 (en) 2024-02-08
IL300824A (en) 2023-04-01
CL2024002398A1 (es) 2024-12-13
JP2025128208A (ja) 2025-09-02
CO2020010465A2 (es) 2020-10-30
KR102721118B1 (ko) 2024-10-25
MX2022016051A (es) 2023-02-01
DK3743070T3 (da) 2025-09-29
US11542259B2 (en) 2023-01-03
JP7690517B2 (ja) 2025-06-10
CR20200358A (es) 2021-02-22
GEP20257770B (en) 2025-06-10
IL276032A (en) 2020-08-31
JP2021511360A (ja) 2021-05-06
BR112020015201A2 (pt) 2020-12-29
SA520412500B1 (ar) 2024-06-23
KR20200115582A (ko) 2020-10-07
EP4647127A2 (fr) 2025-11-12
JP7321165B2 (ja) 2023-08-04
PH12020551208A1 (en) 2021-05-17
JP2023103446A (ja) 2023-07-26
KR20240155380A (ko) 2024-10-28
AU2024205373A1 (en) 2024-08-22
PL3743070T3 (pl) 2025-12-08
AU2019212801B2 (en) 2024-07-04
MA51673A (fr) 2020-12-02
RS67317B1 (sr) 2025-11-28
CA3088200A1 (fr) 2019-08-01
CN117624045A (zh) 2024-03-01
EP3743070A1 (fr) 2020-12-02

Similar Documents

Publication Publication Date Title
MA51673B1 (fr) Composés pour le traitement des troubles dépendants de kinases
SA520412488B1 (ar) مركبات لعلاج اضطرابات معتمدة على كيناز
MA47447B1 (fr) 2-hétéroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides pour le traitement du cancer
MA30906B1 (fr) Composes et compositions en tant quinhibiteurs des proteines kinases
MA33119B1 (fr) Derives de benzofuranyle utilises comme inhibiteurs de la glucokinase
MA49809A1 (fr) Composés utilisés comme inhibiteurs de kinase
MA30952B1 (fr) Cyclopenta [d] pyrimidines utiles en tant qu'inhibiteurs de la proteine kinase akt
MA31655B1 (fr) Pyrimidines cyclopenta [d] hydroxylés et méthoxylés utilisés en tant qu'inhibiteurs de la protéine kinase akt.
MA53861B1 (fr) Modulateurs de promédicaments de la voie de réponse intégrée au stress
BRPI0409173A (pt) compostos e composições como inibidores de proteìna quinase
TN2014000420A1 (fr) Derives d'indole et d'indazole qui activent la mpk
MA37525B1 (fr) Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine
EA201100427A1 (ru) Гетероциклические ингибиторы киназы
BRPI0415210A (pt) compostos e composições como inibidores de proteìna cinase
EA201100426A1 (ru) Бициклические ингибиторы киназы
MA32684B1 (fr) Dérivés de picolinamide en tant qu'inhibiteurs de kinase
MA30076B1 (fr) Carbonylaminopyrrolopyrazoles servant de puissants inhibiteurs de kinases.
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA32110B1 (fr) Derives heterocycliques bicycliques pontes ou derives heterocyclique spiro-bicycliques de pyrazolo [1,5-a] pyrimidines, procedes pour leur preparation et leurs utilisations
MA29785B1 (fr) Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr
CA3139156A1 (fr) Composes pour le traitement de troubles dependant de la kinase
PH12022500015A1 (en) Ccr6 receptor modulators
MA39253B1 (fr) Composés hétéroaryle bicycliques substitués utilisés comme agonistes de rxr
MX2025012483A (es) Moduladores de nk3 y usos de los mismos
FR3073737B1 (fr) La methode de traitement de la rhinosinusite